"Can I get Wegovy or Mounjaro on the NHS - and what will it cost?" It's the question of the year. The honest answer is: yes, but only if you meet strict criteria and can wait. This guide explains, in plain English, how weight-loss injections are funded on the NHS, who qualifies, what they cost privately, and how that compares with Morocco - all with the one rule that never changes: these are prescription medicines that need medical supervision.
🇬🇧 Are weight-loss jabs available on the NHS?
Yes - in principle. NICE approved Wegovy (semaglutide) for NHS use in 2023 and Mounjaro (tirzepatide) in 2024. But "approved" doesn't mean "easy to get". Access runs through specialist (Tier 3) weight-management services, and Mounjaro's wider rollout in GP/primary care is being introduced in phases over several years. In practice, availability depends heavily on where you live (your local Integrated Care Board) - the so-called postcode lottery - and waiting lists can be long.
🎯 NHS eligibility: who qualifies
The thresholds are strict and changing in stages:
- Mounjaro (NHS primary care): the current first cohort generally requires a BMI of 40 or more (lower with ethnic adjustment) plus at least four weight-related conditions (such as type 2 diabetes, high blood pressure, high cholesterol, sleep apnoea, cardiovascular disease). Criteria are scheduled to broaden over 2026-2027.
- Wegovy (NHS): provided via specialist Tier 3 services, typically for a BMI of 35+ with health conditions.
- Waiting times can run from several months to two years depending on the service.
In most cases your GP can't directly start these injections; you're referred to a specialist weight-management service that decides. Even then, demand vastly outstrips capacity.
💳 The private route in the UK
Because NHS access is narrow and slow, many people go private. Through a GPhC-registered pharmacy, after a clinical assessment, treatment is generally available from a BMI of 30 (or 27 with a weight-related condition), with no waiting list. Indicative private cost is roughly £100-£250+ per month depending on the medicine and dose.
The MHRA has repeatedly warned about counterfeit weight-loss pens sold online. Any provider supplying these medicines without a proper clinical assessment is operating outside UK rules. Never buy from social media sellers or unregulated sites.
⚠️ Ozempic is not Wegovy
Wegovy and Ozempic both contain semaglutide, but they are not the same: Wegovy is licensed for weight management, while Ozempic is a type 2 diabetes medicine and is not intended for weight loss. Using Ozempic "to slim" is off-label and must never be self-directed.
🇲🇦 Morocco: is it funded?
In Morocco the position is clear: weight-loss medicines are not reimbursed by the public health insurance (AMO / CNSS / CNOPS) for obesity. However, the out-of-pocket price is much lower than UK private rates.
- Ozempic: available on prescription at around 1,099 MAD (~£90 / €100) per box, licensed for type 2 diabetes; not funded for weight loss.
- Wegovy, Saxenda, Mounjaro: rollout in Morocco is ongoing; availability and final pricing are not yet settled.
🇲🇦 The price advantage
Obesity isn't state-funded in Morocco, but a GLP-1 such as Ozempic costs roughly £90 a month versus £100-£250+ privately in the UK - and there's no two-year waiting list. For international patients that gap is real - but it never replaces proper medical supervision.
📊 UK vs Morocco at a glance
| Criteria | 🇬🇧 UK | 🇲🇦 Morocco |
|---|---|---|
| State funding for obesity | NHS, but very restricted | No |
| NHS/public criteria | BMI ≥40 (+4 conditions), phased | N/A |
| Private access | From BMI 30 (or 27 + condition) | On prescription |
| Waiting list | Often long (NHS) | None |
| Out-of-pocket cost | ~£100-250+/mo | Lower (~£90/mo Ozempic) |
⚠️ The key point: supervision, not a quick fix
Funded or not, one thing doesn't change: these are powerful, prescription medicines with side effects (mainly digestive), contraindications and a dose that must be increased gradually. Weight also tends to return after stopping if habits don't change. The thing that actually works is not the pen - it's a supervised programme: assessment, an appropriate prescription if indicated, plus nutrition, activity and regular follow-up.
❓ FAQ
✅ A supervised programme in Morocco
Wherever you live, the right path is medical, not commercial. Evitalink can connect you with a partner doctor in Morocco for a supervised weight-management programme - assessment, an appropriate prescription if indicated, support and follow-up - and, once you reach your goal, affordable body-contouring surgery if needed. Never self-medication.
A supervised weight programme in Morocco
Message us via WhatsApp for a medical assessment with a partner doctor in Morocco - a supervised programme, never just a pen. Free and confidential.
💬 WhatsApp +212 674 577 557 Get a free assessment →Informational only; not medical advice. These are prescription medicines - never take them without a doctor's supervision. Funding rules and prices change; verify the current position.
Sources & references:
• NICE / NHS England - approval and phased rollout of Wegovy and Mounjaro; specialist weight-management pathways, 2023-2026
• UK pharmacy and clinical sources on NHS eligibility cohorts, BMI thresholds and private access, 2026
• MHRA warnings on counterfeit weight-loss products, 2025-2026
• AMO / CNSS Morocco and Evitalink data on availability and pricing of GLP-1 medicines in Morocco, 2026
General information only; not personalised medical advice. Funding rules and prices change - verify the current position with the NHS, a pharmacist or your doctor.